Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study

Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study Susanne Stoelben, Wolfgang Arns, Lutz Renders, J€ urgen Hummel, Anja M€ uhlfeld, Manfred Stangl, Michael Fischereder, Wilfried Gwinner, Barbara Suwelack, Oliver Witzke, Michael D€ urr, Dietrich W. Beelen, Detlef Michel, Peter Lischka, Holger Zimmermann,* Helga R€ ubsamenSchaeff* and Klemens Budde*

[1]  C. Kotton.  CMV: Prevention, Diagnosis and Therapy , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  M. Marschall,et al.  In Vitro Evaluation of the Activities of the Novel Anticytomegalovirus Compound AIC246 (Letermovir) against Herpesviruses and Other Human Pathogenic Viruses , 2011, Antimicrobial Agents and Chemotherapy.

[3]  H. Zimmermann,et al.  The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase , 2011, Journal of Virology.

[4]  H. Zimmermann,et al.  First Report of Successful Treatment of Multidrug‐Resistant Cytomegalovirus Disease with the Novel Anti‐CMV Compound AIC246 , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  C. Lengerke,et al.  Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT , 2011, Bone Marrow Transplantation.

[6]  C. Kotton.  Management of cytomegalovirus infection in solid organ transplantation , 2010, Nature Reviews Nephrology.

[7]  S. Chou,et al.  Antiviral Drug Resistance of Human Cytomegalovirus , 2010, Clinical Microbiology Reviews.

[8]  R. Razonable,et al.  New Developments in the Management of Cytomegalovirus Infection after Solid Organ Transplantation , 2010, Drugs.

[9]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[10]  H. Zimmermann,et al.  InVitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246 , 2010, Antimicrobial Agents and Chemotherapy.

[11]  E. De Clercq,et al.  Drug targets in cytomegalovirus infection. , 2009, Infectious disorders drug targets.

[12]  H. Zimmermann,et al.  Antiviral strategies to combat cytomegalovirus infections in transplant recipients. , 2008, Current opinion in pharmacology.

[13]  P. Sánchez,et al.  Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. , 2008, The Journal of infectious diseases.

[14]  R. Razonable,et al.  Emergence of drug‐resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes , 2007, Clinical transplantation.

[15]  Deepali Kumar,et al.  A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. , 2005, The Journal of infectious diseases.

[16]  R. Khanna,et al.  Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. , 2004, The Lancet. Infectious diseases.

[17]  J. Squifflet,et al.  Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. , 1999, The New England journal of medicine.

[18]  R. Ptak,et al.  Resistance of Human Cytomegalovirus to Benzimidazole Ribonucleosides Maps to Two Open Reading Frames: UL89 and UL56 , 1998, Journal of Virology.

[19]  Angela M Caliendo,et al.  International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. , 2010, Transplantation.

[20]  A. Schreiber,et al.  Antiviral treatment of cytomegalovirus infection and resistant strains. , 2009, Expert opinion on pharmacotherapy.

[21]  T. Illmer,et al.  Detection of beta-herpesviruses in allogenic stem cell recipients by quantitative real-time PCR. , 2006, Journal of virological methods.

[22]  A. Burroughs,et al.  Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. , 2005, Journal of Infectious Diseases.